Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
RecruitingOBSERVATIONAL
Enrollment
200
Participants
Timeline
Start Date
January 1, 2023
Primary Completion Date
December 30, 2025
Study Completion Date
June 1, 2026
Conditions
Metastatic Breast CancerDrug ResistanceHormone Receptor-Positive Breast CancerHER2-positive Breast CancerTriple-Negative Breast Cancer (TNBC)Treatment Decisions
Trial Locations (1)
410013
RECRUITING
Hunan Cancer Hospital, Changsha
All Listed Sponsors
lead
Hunan Cancer Hospital
OTHER
NCT07073755 - Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd | Biotech Hunter | Biotech Hunter